Compare ADMA Biologics Inc (ADMA) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while First Trust NASDAQ 100 Technology Index Fund trades at $311.97. The key difference: First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | QTEC | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $335.74 |
52-Week Low | $7.60 | $207.03 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
QTEC trades at $320.77, up 1.84% with neutral technical signals and bullish moving averages. The ETF provides equal-weighted exposure to Nasdaq-100 technology stocks, recently hitting 52-week highs. Support levels cluster around $313-318 while resistance sits at $324-329. Recent news highlights QTEC's role in tech sector exposure amid AI and chip stock momentum.
The ETF's equal-weight approach diversifies tech sector risk, though concentrated tech exposure remains sensitive to sector volatility. Current technical positioning suggests consolidation near pivot points, with institutional interest balanced by valuation concerns in overheated AI segments. Key risks include sector rotation and macroeconomic pressure on growth stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
